| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1035764564 |
| P356 | DOI | 10.1007/S00280-014-2571-0 |
| P932 | PMC publication ID | 4210372 |
| P698 | PubMed publication ID | 25163570 |
| P50 | author | Mark J Ratain | Q87725760 |
| Richard A. Larson | Q41899936 | ||
| Jan H Beumer | Q49531403 | ||
| P2093 | author name string | Chen Jiang | |
| Jonathan E Kolitz | |||
| Kouros Owzar | |||
| Edwin P Alyea | |||
| Julianne L Holleran | |||
| Merrill J Egorin | |||
| Ravi Vij | |||
| Charles Linker | |||
| William Blum | |||
| Steven Devine | |||
| Susan M Christner | |||
| Lionel D Lewis | |||
| P2860 | cites work | Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices | Q31782805 |
| P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808 | Q34124919 | ||
| Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients | Q34134690 | ||
| Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life | Q34667853 | ||
| Geriatric Pharmacology: Basic and Clinical Considerations* | Q36213480 | ||
| Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study | Q36760924 | ||
| Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients | Q37070285 | ||
| Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation | Q77163063 | ||
| Anatomy of body water and electrolytes | Q79222460 | ||
| Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule | Q79557465 | ||
| Age differences in the water content of the body as related to basal oxygen consumption in males | Q79666551 | ||
| Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation | Q79817891 | ||
| Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation | Q80794543 | ||
| Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes | Q82627459 | ||
| Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia | Q84342632 | ||
| Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination | Q84521305 | ||
| Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. | Q37160635 | ||
| Busulfan in hematopoietic stem cell transplant setting | Q37554387 | ||
| Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization. | Q37624344 | ||
| Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? | Q38185207 | ||
| Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia | Q40627966 | ||
| Cancer pharmacology in the elderly. | Q40897473 | ||
| Glutathione contents of tissues in the aging mouse | Q41645365 | ||
| Association of busulfan area under the curve with veno-occlusive disease following BMT. | Q42556319 | ||
| Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients | Q43796849 | ||
| Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study | Q43951562 | ||
| Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation | Q44110270 | ||
| The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation | Q44383228 | ||
| Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. | Q44806188 | ||
| I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients | Q44830422 | ||
| Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing | Q46091045 | ||
| Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma | Q46365014 | ||
| Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older | Q46433183 | ||
| Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes | Q46525372 | ||
| The effect of comorbidity on 3-year survival of women with primary breast cancer | Q46637774 | ||
| Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study | Q46679444 | ||
| High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen | Q46794136 | ||
| Determination of ideal body weight for drug dosage calculations. | Q47253218 | ||
| Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children | Q47355479 | ||
| Chronopharmacology of high-dose busulfan in children | Q48312416 | ||
| Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. | Q50700201 | ||
| Age and gender dependent levels of glutathione and glutathione S-transferases in human lymphocytes. | Q50858569 | ||
| Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. | Q51676244 | ||
| An interactive computer program for determining areas bounded by drug concentration curves using lagrange interpolation. | Q52325323 | ||
| Longitudinal studies on the rate of decline in renal function with age. | Q55061206 | ||
| Acetaminophen Metabolism After Major Surgery: A Greater Challenge With Increasing Age | Q56637584 | ||
| Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation | Q67919386 | ||
| Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children | Q68045342 | ||
| Busulfan disposition in children | Q68759019 | ||
| Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group | Q70289280 | ||
| Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle | Q71249405 | ||
| Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo) | Q71271912 | ||
| Effect of liver cirrhosis and age on the glutathione concentration in the plasma, erythrocytes, and gastric mucosa of man | Q71294413 | ||
| Adult lean body mass declines with age: some longitudinal observations | Q71543853 | ||
| Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens | Q72858764 | ||
| Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT) | Q73149406 | ||
| Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study | Q73171815 | ||
| Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions | Q73198585 | ||
| Plasma total glutathione concentrations in epileptic patients taking anticonvulsants | Q73943194 | ||
| P433 | issue | 5 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 927-938 | |
| P577 | publication date | 2014-08-28 | |
| P1433 | published in | Cancer Chemotherapy and Pharmacology | Q326137 |
| P1476 | title | Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103) | |
| P478 | volume | 74 |
| Q36125427 | Busulfan dosing algorithm and sampling strategy in stem cell transplantation patients. |
| Q47116870 | Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. |
| Q39747715 | Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients |
| Q42711146 | Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation |
| Q38749764 | Personalised dosing of medicines for children |
| Q50924228 | Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation. |
| Q50802622 | Population pharmacokinetics and pharmacodynamics of busulfan with GSTA1 polymorphisms in patients undergoing allogeneic hematopoietic stem cell transplantation. |
| Q100762129 | Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study |
Search more.